ImmuneMed Inc.: Detailed Company Information & Corporate Profile

Contact top employees from ImmuneMed Inc.

Summary

The company currently specializes in the Biotechnology area. The annual revenue of ImmuneMed Inc. varies between 1 and 10M. To connect with ImmuneMed Inc. employee register on SignalHire.

ImmuneMed Inc. Websiteimmunemed.co.kr
Phone Number+82 269566005
Industries
ImmuneMed Inc. Headquarters address4 Jeongui-ro 8-gil, Songpa-gu,, Seoul, 05836 KR
Company Size1-10 employees
SpecialtiesVirus Infection Treatment, COVID-19, Viral Hepatitis, Autoimmune Diseases, Vimentin-associated Diseases
Founded2000
Estimated Annual Revenue$1 - 10M

Workforce Turnover

Length of Employment

arrow

ImmuneMed Inc.'s workforce includes employees across a wide range of tenure levels.

17% have been with the company for 3 to 4 years33% have been with the company for 5 to 7 years33% have been with the company for 8 to 10 years17% have been with the company for more than 11 years
Contact top employees from ImmuneMed Inc.
Yong Rho
Yong RhoChief Executive Officer
Phone (1)
+82-***-***-7163
Unlock contacts
Nagesh Ipper
Nagesh IpperTeam Leader
Phone (1)
+82-***-***-8188
Unlock contacts

ImmuneMed Inc. Corporate Information: FAQ

ImmuneMed Inc. operates in the Biotech industries. More details can be found on the official website: immunemed.co.kr.
The headquarters of ImmuneMed Inc. are located in Seoul, Republic of Korea.
You can contact ImmuneMed Inc. by phone at +82 269566005.
ImmuneMed Inc. currently employs 1-10 people.
ImmuneMed Inc.'s revenue is approximately 3.1M.

Data Privacy

GDPR Icon

GDPR COMPLIANT

SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.

CCPA Icon

CCPA COMPLIANT

SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.

BACK TO TOP